SangStat Commences Volume Manufacturing of TRANSTAT Technology

Strategic Insights -

SangStat, a biopharmaceutical company, announced that it had commenced volume manufacturing of its TRANSTAT technology, a rapid cartridge-based testing system for haemostasis and coagulation testing. The company has licensed the rights to its TRANSTAT product technology to Diagnostica Stago S.A., a leading European manufacturer of diagnostic products, for exclusive worldwide use in a new diagnostic kit. TRANSTAT technology enables testing of blood or serum specimens in 5-10 minutes.

Key Takeaways:

  • SangStat has commenced volume manufacturing of its TRANSTAT technology, a rapid cartridge-based testing system for haemostasis and coagulation testing.
  • Diagnostica Stago S.A. has acquired exclusive worldwide rights to utilize TRANSTAT technology in a new diagnostic kit for testing D-Dimer levels, which are associated with serious coagulation disorders.
  • SangStat will manufacture the kit cartridges for Stago on an exclusive basis, with Stago obligated to meet minimum purchase requirements and pay royalties on net sales.
  • The agreement will help SangStat establish early commercial quantities of the TRANSTAT product line and generate near-term revenues, meeting two of its corporate objectives.
  • SangStat is a biopharmaceutical company that has developed a range of therapeutic and monitoring products for organ transplantation, including 11 products and product candidates, with several in advanced stages of development.

Statistics:

  • 5-10 minutes: the testing time enabled by TRANSTAT technology.
  • 11: the number of products and product candidates developed by SangStat.
  • 2: the number of corporate objectives met by the agreement with Diagnostica Stago S.A.

Sources:

  • Business Wire, January 23, 1995
  • SangStat Medical Corp.
  • Diagnostica Stago S.A.